首页> 外文期刊>Asia Pacific journal of clinical nutrition >25 hydroxy vitamin D is higher when a renal multivitamin is given with cholecalciferol at hemodialysis
【24h】

25 hydroxy vitamin D is higher when a renal multivitamin is given with cholecalciferol at hemodialysis

机译:血液透析中与胆钙化固醇同时服用肾脏多种维生素时,25羟基维生素D较高

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Objectives: Seventy six hemodialysis (HD) patients were used in a prospective randomized and clinical trial to determine if a multivitamin with vitamin D (cholecalciferol 12,000 IU/week) given during dialysis would improve the vitamin D status of hemodialysis subjects. Methods and Study Design: Subjects were randomly assigned to two groups: 37 subjects were in the renal multivitamin without vitamin D (MV) group and 39 subjects were in a multivitamin route with vitamin D (MVD) group (12,000 IU of cholecalciferol per week). All subjects were given 2 multivitamin tablets at their 3 HD sessions each week for 20 weeks. Serum 25(OH)D, calcium (Ca), and phosphorus (P) levels were evaluated. Results: At baseline, mean serum 25(OH)D were below adequate (<30 ng/mL) in the MV group (23.5+/-12.2 ng/mL) and in the MVD group (20.8+/-10.3 ng/mL). A significant increase was seen in serum 25(OH)D levels (37.7+/-11.4 ng/mL; p<0.001) in the MVD group after vitamin D supplementation with no rise in the MV group value (21.7+/-11.4 ng/mL; p=0.06). Prior to supplementation, 17.9% of patients in the MVD group had adequate serum 25(OH)D level and post supplementation 76.9% in the MVD group had adequate serum 25(OH)D. In the MV group, 18.9% subjects had adequate serum 25(OH)D levels at baseline with 18.9% having 25(OH)D >30 ng/mL at the end of the study. There were no significant differences in group values for serum Ca and P. Conclusion: The majority of HD subjects given a multivitamin with cholecalciferol at dialysis had improvement in their vitamin D status.
机译:背景与目的:在一项前瞻性随机和临床试验中,对76名血液透析(HD)患者进行了研究,以确定透析期间给予维生素D的复合维生素(胆钙化固醇12,000 IU /周)是否会改善血液透析受试者的维生素D状况。方法和研究设计:将受试者随机分为两组:37名受试者处于无维生素D的肾脏多种维生素(MV)组,而39名受试者处于维生素D(MVD)的多种维生素途径(每周12,000 IU胆钙化醇) 。每周在3个高清环节向所有受试者提供2种复合维生素片,持续20周。评估血清25(OH)D,钙(Ca)和磷(P)的水平。结果:基线时,MV组(23.5 +/- 12.2 ng / mL)和MVD组(20.8 +/- 10.3 ng / mL)的平均血清25(OH)D低于适当水平(<30 ng / mL)。 )。补充维生素D后MVD组的血清25(OH)D水平显着增加(37.7 +/- 11.4 ng / mL; p <0.001),而MV组值没有升高(21.7 +/- 11.4 ng) /mL;p=0.06)。在补充之前,MVD组中有17.9%的患者血清25(OH)D足够,补充后在MVD组中76.9%的患者具有足够的血清25(OH)D。在MV组中,有18.9%的受试者在基线时有足够的血清25(OH)D水平,而在研究结束时,有18.9%的受试者的25(OH)D> 30 ng / mL。血清Ca和P的组值无显着差异。结论:大多数HD患者在透析时接受含维生素钙和胆钙化固醇的维生素D状况均有改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号